A Phase 1-2 dose-escalation and expansion study of ST101 in patients with advanced unresectable and metastatic solid tumors


NCT Number:



Study Status:






With this research study, we want to find out which dose of ST101 is tolerable and effective for people with different types of cancer. We also want to see what the body does to ST101, where ST101 goes in the body, and how long it stays in the body. This study is the first time we have given ST101 to humans. Drugs that can only be used in research are sometimes called 'investigational drugs.' Investigational means the study drug/formulation/medical device being tested is not approved by the U.S. Food and Drug Administration (FDA).

Are you Eligible? (Inclusion Criteria)

  • Are you at least 18 years of age or older?
  • Are you able to perform every day tasks independently?
  • Did your cancer progress or not respond to previous treatment?
  • Do you have adequate organ function?

Specialty Area(s)

Bladder Cancer , Brain and Spinal Tumors, Breast Cancer, Esophageal Cancer, Gynecologic Cancers, Head and Neck/Oral Cancers, Kidney Cancer/Adrenal Cancer, Lung cancer, Skin cancers, Melanoma, Prostate Cancer, Sarcomas (Bone and Soft Tissue), Stomach Cancer, Testicular Cancer, Thyroid Cancer

Principal Investigator

Profile Headshot
  • Deputy Director, Division of Neuro-Oncology

Trial Location(s)

CUIMC/Herbert Irving Pavilion
161 Fort Washington Avenue
New York, NY 10032